Status:
RECRUITING
Breast Cancer PSMA PET
Lead Sponsor:
Ahmad Shariftabrizi
Collaborating Sponsors:
Progenics Pharmaceuticals, Inc.
Conditions:
Triple Negative Breast Cancer
Eligibility:
FEMALE
18-90 years
Phase:
NA
Brief Summary
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/...
Detailed Description
Prostate Specific Membrane Antigen (PSMA) is not only expressed in prostate cancer and its metastases, but also it is expressed on the neovasculature of many other solid tumors including gastric, lung...
Eligibility Criteria
Inclusion
- Female \>= 18 years of age
- Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
- Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
Exclusion
- Patients with known active other malignancy.
- Unable to tolerate PET/CT procedure.
- Pregnant or breastfeeding.
- Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
Key Trial Info
Start Date :
August 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 29 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06586047
Start Date
August 29 2024
End Date
August 29 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa Healthcare
Iowa City, Iowa, United States, 52242